Dyslipoproteinemias represent a group of disorders closely related t o alterations of cholesterol and triglycerides. The alterations of these lipids are considered important risk factors in coronary heart disease and indicate t h e need for clinically effective and safe drugs.
tive disease represents one of the highest causes of morbidity and mortality in the most productive age group in the civilized world. The disabling consequences of this disease are greatest among individuals between 45 and 60 years of age (76) . Therefore the development of clinically effective drugs to manage dyslipidemias demands a high priority.
In the study of the pharmacologic effects of hypolipidemic agents, the status of blood cholesterol and triglyceride levels is a mere reflection of the metabolic interactions taking place in various organs and tissues which influence the metabolism and transport of lipoproteins (81) . Hypolipidemic agents constitute a group of heterogeneous compounds with diverse biochemical targets, ranging from the inhibition of cholesterol biosynthesis within liver cells to the blockade of cholesterol absorption in the intestinal tract. This means that the effectiveness of the hypolipidemic agent will vary depending on which step in lipid metabolism is affected as well as the phenotypic alteration of circulating lipoproteins.
THERAPEUTIC BENEFIT OF HYPOLIPIDEMICS
Most lipid regulating agents are used by necessity for prolonged periods of time, thus posing obvious concern for long-term safety. For these reasons the results of chronic studies in rodents are reviewed since these constitute the primary basis for extrapolating safety results to humans (12, 60) . Several hypolipidemic agents have been studied in the last few years, The results of safety studies have sparked significant debate and the interpretation of findings became increasingly difficult due to our lack of knowledge on the pathogenesis of these possibly drug-associated changes (15, 36) .
Intrinsically, the need for accurate and conservative interpretation of lesions emerges in order to establish adequate risk/benefit assessments (32). In the case of hypolipidemic agents, the administration of these agents to man must take into consideration the risk factors involved in cardiovascular disease. Clinically sound diagnostic criteria will identify only those patients who would benefit by this approach. Recently discovered hypolipidemic agents possess a favorable risk/benefit ratio, since they represent a significant advance in the treatment of the disease, replace an obsolete medical approach, significantly influence the clinical outcome of the disease, and may prove effective in the primary or secondary prevention of disease with tangible social advantages (12, 40) .
GEMFIBROZIL SAFETY STUDIES
For the past three years we have been evaluating the safety of gemfibrozil in animal studies. The details of these studies are available in the literature (25). Gemfibrozil is chemically recognized as 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoic acid ( Figure 1 ) and possesses lipid-regulating properties. In biochemical studies, the drug increased the incorporation of labeled acetate and octanoate into liver sterol fractions, as opposed to more conventional metabolically active agents which inhibited these steps (48) . The decrease of serum lipids produced by gemfibrozil is primarily through the reduction of triglycerides together with variable reductions in the cholesterol fraction. However, these changes in lipid fractions are reflected in a decrease of very low density lipoproteins (VLDL), to a lesser extent in low density lipoproteins (LDL) and clear increases in the high density lipoproteins (HDL). The increase in HDL is assumed to be beneficial since it both blocks cholesterol deposition into the arterial intima and removes cholesterol from peripheral sites back to the liver for excretion. Therefore gemfibrozil should influence the pathogenesis of atherosclerosis (75) .
In the general safety evaluation of carcinogenesis potential, studies were conducted with gemfibrozil in rodents under conventional protocols (25, 57). The target organ of hypolipidemic toxicity 'is confined to the liver and changes due to these drugs are represented by the development of nodules or tumors (58). Highlights of the results from the long term rodent studies are shown in Table  1 . Gemfibrozil, like clofibrate, did not increase the tumor incidence in male or female mice or in female rats. Unlike these two compounds, the literature reveals that tibric acid, nafenopin, WY14643 and BR931 elicit a tumor response in both sexes of rats and mice (54, 61, 62, (64) (65) (66) 91 
First, the natural history of liver tumors must be understood to facilitate the evaluation of drug effects. Differences in the spontaneous liver tumor incidence among various reports (2, 5, 13, 28, 30, 31, 45, 46, 59, 69, 70, 72, 86) , could be due to a variety of factors. Among these, the histotyping criteria used to classify the tumors is decidedly relevant since up until now no consensus has been reached as to when areas of hepatocyte proliferation become space-occupying lesions (19, 87) . This lack of consensus becomes more pivotal since in some cases, foci of hyperplasia, hyperplastic nodules and hepatocellular carcinoma are summed together for statistical evaluation of the overall incidence of hepatic neoplasia. In other instances, the raw incidences of these entities are not actuarially adjusted to reflect dose and age response relationships. However, the characteristic identifying features of liver cell carcinoma are obvious (80) , and metastasizing potential seems to be a .determining property (7) ( Figure 2 ).
CONSIDERATIONS ON RODENT LIVER TUMORS
Important findings have emerged from the study of the biology of these neoplasms which extend beyond the mere statistical process as they determine the extrapolation of these re- 
ADD ITI o N AL STUD I ES AND 0 BS E RVATI o N s TUMORS
We propose that some aspects of the biology of hypolipidemic-induced nodules must be considered in parallel to the morphological criteria in order to determine the relevance of these tumors in human safety (Table 3 ). Cellular features that characterize nodules in rats are useful parameters which provide clues to their behavior. None of the tumors in our studies revealed local invasiveness or distant or local metastases. No differences were noted in the onset or average latency period (15,25). Failure of full differentiation and loss of function have been established in human hepatocellular carcinoma and surrounding non-neoplastic liver (27).
Observations were also extended by means of studying the subcellular architecture of proliferating hepatocytes within drug-related tumors. Increased peroxisomes were observed in a similar fashion to drug-induced peroxisome increase in normal hepatocytes from surrounding tissue (Figures 4 and 5 ). Therefore, autonomy, a constant feature of neoplastic cells, had not been completely acquired (24) ( Table 4 ). Peroxisomes-constitute unique, natural subcellular markers in the liver cell (14, 39). Their induction has been well studied in male rat liver under the influence of hypolipidemics (1, 18, 26, 38, 43, 44, 51, 61, 63, 77, 85), a finding originally reported with clofibrate (37). Some agents modify the internal structure of the organelle (26, 85), ( Figure 5 ).
The loss of normal subcellular architecture and intervening cell necrosis (8, 11) have also been identified as critical steps in the sequential series of events leading to hepatic neoplasia (20-23, 52). Peroxisome induction within proliferating hepatocytes within nodules constitute functional markers of drug effects (89) and led us to study the behavior of this organelle in several species for the purposes of confirming specificity and/or sensitivity.
Liver samples were obtained from the re- peated-dose studies as shown in Table 5 . Based on correlated qualitative morphologic studies, the peroxisome population varied greatly. These particles appeared in clusters in scattered cytoplasmic areas and significant variations were also related to the lobular disposition of hepatocytes. In the absence of quantitative data, peroxisomes were abundant in mouse liver cells and no peroxisome proliferation was detected in the liver of rhesus monkeys, beagle dogs and marmosets (Figures 6 to 10). These and other species are under study by quantitative methodology in our laboratory. We also had the opportunity to study percutaneous liver biopsies of patients receiving gemfibrozil for over 2 years. No subcellular pathology was noted other than fatty change which is expected in their particular dyslipidemic state (16), (Figures 11 to 13 ). Hepatotoxicity by liver biopsy has been established previously with other compounds (3). A preliminary, report on the quantitative assay 'of the peroxisome population in liver cells from these patients failed to reveal large increases (17) (Table 6 ). This finding is in contrast to the male rat. Peroxisomes appear to increase in hepatic injury (82) . The conclusions from these studies were that the male rat represents an exquisitely sensitive model system for demonstrating the action of hypolipidemic compounds without comparable reactions in the liver of higher vertebrates (10,16) ( Figures  14-15 ).
P E RTAl N I N G TO HYPO LI PI D EM I C -I N D uc E D LIVER

G ENOTOX~C~TY STUD I ES WITH H Y POL1 PI DEMlCS
Aside from this unusual peroxisome-proliferating reaction which is superimposed on the liver subjected to a significant metabolic overload (animals are fed the maximum tolerable dose over most of their life span), there are other influencing factors that have not been fully explored (49) (Figure 16 ). It is essential to understand that these liver nodules are not the result of a direct carcinogenic effect via genotoxic mechanisms. Influencing factors include the rate of hepatic cell proliferation in the adult rat under constant exposure to the agents and the influences brought about by age on the rate of xenobiotic metabolism and biotransformation capacity (54, 66) .
Further, covalent binding capacity and potential for DNA damage/repair in vivo are important alternatives to qualify the effects of these drugs as hepatoproliferating agents (4). In vitro and in vivo studies were conducted to de la IGLESIA AND FARBER TOXICOLOGIC PATHOLOGY. 1. Subcellular structures: increased rough endoplasmic reticulum, more lysosomes, paucity of organelles. loss of enzymes within organelles, loss of response to pharmacologic stimuli (i.e. loss of peroxisome induction).
Functional markers:
determine if gemfibrozil demonstrates genotoxicant characteristics (Table '7) . Bacterial mutagenesis assays were conducted under a comprehensive protocol and have been re-ported earlier (25). The rat metabolites which could have accounted for the formation of electrophilic reactives or genotoxicity, were isolated, unequivocally characterized, synthesized, and tested in a similar fashion as the parent compound, all with similar negative results (25). The structures of the metabolites are shown in Figure 17 . Additional in vitro tests included cell mutation assays at the HGRPT locus and sister chromatid exchange as well as cytogenetic studies, corroborating the lack of genotoxic potential (unpublished data) (Table 7) . Other studies have also shown lack of genotoxicity with other lipid-lowering compounds in bacterial and mammalian cell assays (50, 67, 90) including thymidine incorporation in stimulated splenic lymphocytes (91) .
IN VlVO SHORT-TERM CARCINOGENESIS TESTS FOR lNlTlATlON OR PROMOTION
The literature is scarce regarding initiation/ promotion studies with this class of compounds although the lack of genotoxicity as well as the equivocal tumor data should have stimulated more research (54) . In our laboratories, initiation/promotion protocols were developed using clofibrate in short-term in vivo hepatocarcinogenesis (88) and lung adenoma bioassays (83) without eliciting a positive response although different results were found with nafenopin (54). These compounds tested did not induce a significant increase in focal areas with gamma-glutamyl transpeptidase expression (35, 41, 68) following single dose. These results compared well with positive findings from well-known carcinogens such as benzo(a)pyrene, DMBA, 3-methylcholantrene, lI2-dimethylhydrazine and butylnitrosourea in the same scheme (88) .
The primary approach was on a three-tiered program, with the first step being a single dose study; the second step as multiple doses (usually three), and the third by exposure for 2 to 3 weeks or more in the diet. Longer periods of exposure in diet, for up to 13 weeks, failed to demonstrate enzyme-positive islands. Studies of frank carcinogens using the same program showed that these exposure intervals should have given positive results (74) . Promotion bioassays that explore this unusual proliferative stimuli as well as modification of existing protocols (54, 58, 78, 88, 93) are obviously needed to determine a differentiation from spontaneously active foci (53) .
SIGNIFICANCE OF TUMORS A N D RISK EVALUATION
From the preceding discussion, we conclude that a statistical analysis of various hepatocellular tumor types or nodules alone is of doubtful value in prediction of human risk (10, 15, 16). Enough biological differences in the characteristics of these tumors exist to preclude direct extrapolation. (Table 8 ). The majority of these tumor are species and sex specific, show a variety of genetic enhancements and demonstrate selective increase independent of dose (5, 46, 71, 86) . Although the increases of tumors may represent an exaggeration of pre-existing occurrences native to the species, the wide variations reported in the literature indicate the presence of additional confounding phenomena (23, 32, 79), including in vivo tumor inhibition (29). An encouraging aspect is the lack of effect of hypolipidemics in several in vitro and in vivo genotoxicity models including some organspecific experimental designs (15, 53, 90) .
Pharmacologic properties seen in rodent liver, such as peroxisomal proliferation, are not reflected in humans (16, 33, 34, 42) . Table  9 lists the key safety issues for hypolipidemics. Regarding the neoplastic response in rodents, the proliferative changes seen do not appear to represent a true cancer-forming process due to the lack of cell transformation. The hypolipidemic-related hepatocyte proliferation does not lead to tumors or nodules via controlled cell growth mechanisms inherent in the trophic or stimulatory properties of these compounds (54, 73, 74) , or by otherwise not recognized epigenetic mechanisms (47) . The prolonged latency of some of these tumors would include the possibility of low level tumorigenic potential requiring a protracted course of evolution. Another important factor, though not well studied, could be the reversibility of these proliferations.
Hypolipidemics have been regarded as a group of chemical hepatocarcinogens with peroxisome-proliferating capacity (61) , although the diversity of chemical structures and different biological behavior of the nodules induced by these agents prevent generalization. (Figure 18 have been discontinued from clinical research due to unacceptably high side effects rate or overt hepatoxicity (3, 58). An anticipated consequence to the long-term exposure of rodents is that a certain number of neoplasms should occur together with a discrete b~ological behavior (Table 10 ). The lack of these effects would identify a unique agent, acting via com- 
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I D I O S Y N C R A T I C RESPONSE OF MALE R A T L I V E R
RESPONSE
I. Are liver nodules representative of a neoplastic response in rodents?
The male rat liver responds atypically to long term administration of hypolipidemics. . .
No neoplastic response evoked in other species.
The liver o f several species, including man, does not reveal the proliferative changes. There are several differences in tumor biology, lack of genotoxicity and negative short-term organ-specific bioassays.
The relevance of the results i s taken with reserve. Safety assessment value may improve with close medical surveillance and therapy aimed at specific phenotypic alteration.
Are peroxisome-inducing hypolipidemics true chemical carcinogens?
3. Are the results from rodent bioassays of predictive value and how can these contribute to safety assessment? 0 CH 7 I " 1. Metabolically active hypolipidemic agents most likely will affect rat liver (particularly males) with resulting 2. T h e hepatoproliferative response of rats should be confined to preneoplastic changes and not include fully 3. The therapeutic objective is confined t o patients at risk with well-characterized lipoprotein pathology. 4. Due to t h e lack of genotoxicity and lack of activity in organ-specific bioassays, further research should be encouraged hepatocyte proliferations. developed cancerous lesions or metastases.
to elucidate the mechanism of cell proliferation. pletely different and unknown mechanisms (50) .
In considering the predictive value of the animal data, the risk is minimized because of this lack of correlation. Semiquantitative methods have been proposed to gauge carcinogen potency (6, 79,92). However, it may not be always possible to make this calculation since these agents are given to patients with well-characterized lipoprotein phenotypic alteration and not for the indiscriminant treatment of elevated blood lipids.
Thus, when all of these results and considerations are viewed in a composite fashion, the equivocal nature of the bioassays, paralleled with clinically useful parameters for risks evaluation, result in qualitative criteria that allow adequate evaluation by regulatory agencies without restricting the availability of these compounds for proper therapeutic application. June 30/82.
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